Capital News

Chronic Inducible Urticaria Market, Size, Share, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Chronic Inducible Urticaria Market, Size, Share, Trends, Epidemiology Forecast till 2030

August 07
20:26 2020
Chronic Inducible Urticaria Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast 2030’ report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Chronic Inducible Urticaria (CIndU) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chronic Inducible Urticaria is a group of chronic urticarias characterized by the appearance of recurrent wheals, recurrent angioedema, or both, as a response to specific triggers. 

 

The market size of Chronic Inducible Urticaria is anticipated to rise at a significant CAGR during the study period of 2017–2030. Among all 7MM, the United States accounted for the largest Chronic Inducible Urticaria market size.  

 

 

 

Among EU5 countries, Germany had the largest market size of Chronic Inducible Urticaria, with USD 172 million in 2017, while Spain had the smallest Chronic Inducible Urticaria market size with USD 104.5 million in 2017. 

 

Chronic Inducible Urticaria market drivers

  • Need for curative therapy
  • Increasing awareness
  • Rising prevalence

 

Chronic Inducible Urticaria market barriers

  • Need for biomarkers
  • Complex pathophysiology
  • Patient adherence
  • Need for Chronic Inducible Urticaria specific population studies 

 

The therapeutic goal of Chronic Inducible Urticaria management primarily focuses on achieving complete symptom control by trigger avoidance and desensitization, blocking the effects of mast cell mediators (non- sedating, second-generation antihistamines), and prevention of mast cell degranulation. Currently, there is no approved therapy for Chronic Inducible Urticaria treatment apart from symptomatic management. The pipeline scenario does not show a particularly close picture with only one major player making significant inroads in the largely untapped market. AK002 (Antolimab), being developed by Allakos Pharma, is the only drug with the potential to enter the arena during the forecast period and has completed Phase II trials.

 

Request for sample pages

Table of contents

1 Key Insights

2 Executive Summary of Chronic Inducible Urticaria

3 SWOT Analysis for Chronic Inducible Urticaria

4 Chronic Inducible Urticaria Epidemiology Overview at a Glance

4.1 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2017

4.2 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2030

5 Chronic Inducible Urticaria Market Overview at a Glance

5.1 Market Share (%) Distribution of Chronic Inducible Urticaria in 2017

5.2 Market Share (%) Distribution of Chronic Inducible Urticaria in 2030

6 Disease Background and Overview

6.1 Introduction

6.2 Types

6.3 Pathophysiology

6.4 Clinical features

6.5 Diagnosis

6.6 Clinical manifestation

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Total Prevalent Population of CIndU in 7MM

7.3 Assumptions and Rationale: 7MM

8 Country Wise-Epidemiology of Chronic Inducible Urticaria

8.1 The United States

8.1.1 Diagnosed Prevalent cases of CU in the United States

8.1.2 Diagnosed Prevalent cases of CIndU in the United States

8.1.3 Prevalence of Chronic Inducible Urticaria by Types in the United States

8.2 EU5

8.2.1 Germany

8.2.2 France

8.2.3 Italy

8.2.4 Spain

8.2.5 The United Kingdom

8.3 Japan

8.3.1 Diagnosed Prevalent cases of CU in Japan

8.3.2 Diagnosed Prevalent cases of CIndU in Japan

8.3.3 Prevalence of Chronic Inducible Urticaria by Types in Japan

9 Treatment and Management

9.1 Guidelines

10 Case Study

10.1 Severe cold urticaria including anaphylaxis

10.2 Severe symptomatic dermographism (urticaria factitia)

11 Patient Journey

12 Unmet Needs

13 Emerging Therapies

13.1 AK002: Allakos Inc.

13.1.1 Product Description

13.1.2 Clinical Development

13.1.3 Safety and Efficacy

14 Other Promising Therapies

14.1 CDX-0159: Celldex Therapeutics

14.1.1 Product Description

14.1.2 Clinical Development

14.1.3 Safety and Efficacy

15 Chronic Inducible Urticaria: Seven Major Market Analysis

15.1 Key Findings

15.2 Market Size of Chronic Inducible Urticaria (CIndU) in 7MM

16 Market Outlook by Country

16.1 Assumption and Rationale

16.2 United States

16.2.1 Total Market size of Chronic Inducible Urticaria (CIndU)

16.2.2 Chronic Inducible Urticaria Market Size by Therapies

16.3 Germany

16.3.1 Total Market size of Chronic Inducible Urticaria (CIndU)

16.3.2 Chronic Inducible Urticaria Market Size by Therapies

16.4 France

16.4.1 Total Market size of Chronic Inducible Urticaria (CIndU)

16.4.2 Chronic Inducible Urticaria Market Size by Therapies

16.5 Italy

16.5.1 Total Market size of Chronic Inducible Urticaria (CIndU)

16.5.2 Chronic Inducible Urticaria Market Size by Therapies

16.6 Spain

16.6.1 Total Market size of Chronic Inducible Urticaria (CIndU)

16.6.2 Chronic Inducible Urticaria Market Size by Therapies

16.7 UK

16.7.1 Total Market size of Chronic Inducible Urticaria (CIndU)

16.7.2 Chronic Inducible Urticaria Market Size by Therapies

16.8 Japan

16.8.1 Total Market size of Chronic Inducible Urticaria (CIndU)

16.8.2 Chronic Inducible Urticaria Market Size by Therapies

17 Market Drivers

18 Market Barriers

19 Appendix

19.1 Report Methodology

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/capitalnews/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share